Abstract Library

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#2762 Finding the Risk Factors Associated with Neuroendocrine Tumors of Rectum

Introduction: Neuroendocrine tumors usually exhibits aggressive clinical behaviour and exclusive histopathological features. 60 to 70% of rectal NETs are asymptomatic.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Fatima A

Authors: Fatima A, Zai S,

Keywords: colonoscopy, rectal NETs, low HDL-C level,

#2114 Significance of Biochemical Testing in Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are frequently diagnosed late in the course of the disease. Several biomarkers have been proposed in the literature for diagnosis in patients with these tumors.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Athar A,

Keywords: Biochemical markers, PNETs, Better prognosis,

#1817 Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer

Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Dureja S

Authors: Dureja S, Thakral P, Pant V, Pallavi U, Vindhya M,

Keywords: PRRT, radiosensitizer,

#1002 Retrospective Study of MIBG Therapy for Phaeochromocytoma (PH) and Paraganglioma (PG): The Christie Experience

Introduction: PH & PG are rare neuroendocrine tumors treated with MIBG but protocols are not standardized and reported results are variable.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Salih Z, Fletcher K, Clay V, Manoharan P, Hawkins R,

Keywords: mibg,